Cyttron II is a consortium of 14 academic and industrial partners. Together we further develop and integrate bioimaging technologies, in order to develop powerful new diagnostics and treatments. Cyttron II is funded by the FES 2009 programme (50% government funding, 25% public funding, 25% private funding). The consortium continues on the successful clusters of its two parent consortia.
The projects of Cyttron II continue on the successful projects of two predecessor consortia: Cyttron and MIIHD. These parent consortia developed new technologies in the period 2004-2009 that form the basis for the bioimaging tools for diagnosis that we will work on in Cyttron II. The successful outcomes of the parent consortia are:
A multimodal database/visualization platform
Novel biomarkers of heart disease for bioimaging
New technologies for multimodal imaging correlative imaging and digital pathology
Click here for an overview of Cyttron I publications
An all-embracing picture is required for a successful diagnosis and to set off an optimal treatment. Since a single technology that can achieve this complete image does not exist, we need different types of equipment that deliver different types of data. Integrating the resulting quantitative data of these different sources is of utmost importance to understand the whole picture. At the same time current technologies have to be developed further for a fully integrative approach.
Over the period 2004-2007, the Cyttron I consortium created:
2 new bioimaging technology products marketed by Netherlands-based companies within four years
7 new patent applications
5 new copyrighted software products
5 new industrial partnerships
In excess of 170 scientific publications
Given this track record and the increased private involvement in this new consortium, we expect an increased economic output for Cyttron II.
Personalised medicine will become more and more important in the 21st century. In personalised medicine, therapies are made-to-measure and thus carefully customised for each individual patient. This requires detailed diagnosis and monitoring. Bioimaging technologies have a strong track record in this field, ranging from microscopy to MRI. Their integration is hence expected to play an important role in developing personalised medicine.
To make the field we work in more accessible to a broad public, we will set up an exhibition on the cell and continue our school visiting program together with NCB Naturalis.